Tazobactum%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many beta-lactamase enzymes, thereby extending its spectrum of activity. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections (including diabetic foot infections) * Community-acquired pneumonia * Nosocomial pneumonia * Febrile neutropenia (in combination with an appropriate antipseudomonal agent if indicated) ## Adult Dosing * **Standard Dosing:** 3.375 grams (3 grams piperacillin/0.375 grams tazobactam) or 4.5 grams (4 grams piperacillin/0.5 grams tazobactam) intravenously every 6 or 8 hours. * **Dosing Frequency:** Based on severity of infection, patient's clinical status, and renal function. * **Maximum Dose:** Not explicitly defined but typically guided by clinical response and renal function. Dosing for severe infections may extend beyond standard regimens. ## Pediatric Dosing * **Infants and Children < 2 years:** Dosing is generally based on piperacillin weight-based recommendations, often at 100 mg/kg/day of piperacillin divided every 6-8 hours, with tazobactam added at a 1:8 ratio. Specific dosing can be complex and may depend on the indication (e.g., febrile neutropenia) and local protocols. * **Children ≥ 2 years:** Dosing is often guided by adult dosing, with consideration for piperacillin component. For example, 3.375 grams every 8 hours or 4.5 grams every 8 hours. Weight-based dosing up to the adult maximum may be used. * **Consultation:** Pediatric dosing requires careful consideration of indication, severity, weight, and renal function. Consultation with a pediatric infectious disease specialist or pharmacist is often recommended. ## Dose Adjustments * **Renal Impairment:** * CrCl ≥ 40 mL/min: No adjustment needed. * CrCl 20-39 mL/min: Administer usual dose every 8 hours. * CrCl < 20 mL/min: Administer usual dose every 12 hours. * **Hemodialysis:** Administer usual dose every 12 hours and supplement with an additional 1.125 grams after each dialysis session. * **Hepatic Impairment:** No specific dose adjustment is typically required, but caution is advised. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, other penicillins, or any component of the formulation. * History of allergic reaction to beta-lactam antibiotics. ## Adverse Effects * **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, pruritus, fever, thrombocytosis. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures, leukopenia, neutropenia, thrombocytopenia, elevated liver enzymes, interstitial nephritis. ## Key Drug Interactions * **Probenecid:** May increase and prolong serum concentrations of piperacillin. * **Neuromuscular blocking agents:** Piperacillin may prolong the action of vecuronium. * **Warfarin:** May decrease the effect of warfarin; monitor INR closely. * **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels. * **Aminoglycosides:** While often co-administered for broader coverage, consider potential for antagonism or increased nephrotoxicity if used concurrently. Compatibility in infusion should be assessed. ## Monitoring * Renal function (CrCl) for dose adjustment. * Liver function tests. * Hematologic parameters (CBC with differential and platelets). * Signs and symptoms of infection. * Signs of hypersensitivity reactions. * Stool for *C. difficile* if diarrhea develops. ## Clinical Pearls * Piperacillin/tazobactam is a broad-spectrum agent often used for empiric therapy of serious infections, including those caused by Gram-negative organisms like *Pseudomonas aeruginosa*. * Ensure adequate hydration during administration. * Administer by intravenous infusion over at least 30 minutes. Rapid infusion may increase the risk of seizures. * Reconstituted solutions are generally stable for 24 hours at room temperature or 48 hours if refrigerated. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for complete details and to ensure appropriate patient care.*